TWST Shareholder Alert: KAPLAN FOX Announces Investigation of Twist Bioscience Corp. for Potential Securities Fraud

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( is investigating claims on behalf of investors of Twist Bioscience Corporation ("Twist") TWST.

If you would like to discuss our investigation, please contact us by emailing or by calling (212) 687-1980.

On November 15, 2022, before the market opened, Scorpion Capital published an investigative report concerning Twist titled "Twist Bioscience TWST A Cash-Burning Inferno That Is Not A Going Concern, Operating A Ponzi-Like Scheme That Will End In Bankruptcy. Just Another "Synthetic Biology" Swindle, This Time With An Absurd "Silicon DNA Chip" And Financials So Phony It May Be Criminal. Target Price: $0."

On November 15, 2022, Twist shares opened at $28.76 per share, a decline of $9.24 per share from the closing price on November 14, 2022 of $38 per share, a decline of over 24%, on very high volume.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at

If you have any questions about this investigation, please contact:

Jeffrey P. Campisi
850 Third Avenue, 14th Floor
New York, New York 10022
(212) 687-1980

Laurence D. King
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707

Posted In: NewsLegalPress Releases